Ketamine transdermal patch - Shenox Pharmaceuticals
Alternative Names: SHX-001Latest Information Update: 28 Jan 2022
Price :
$50 *
At a glance
- Originator Shenox Pharmaceuticals
- Class Amines; Analgesics; Antidepressants; Antihyperglycaemics; Antiparkinsonians; Anxiolytics; Behavioural disorder therapies; Chlorobenzenes; Cyclohexanes; General anaesthetics; Ketones; Mood stabilisers; Neuroprotectants; Neuropsychotherapeutics; Obesity therapies; Small molecules
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Major depressive disorder
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for phase-I development in Major depressive disorder(In the elderly, In adults) in USA (Transdermal, Patch)
- 28 Dec 2018 Phase-I clinical trials in Major depressive disorder (In adults, In the elderly) in USA (Transdermal) (NCT03721900) (Shenox Pharmaceuticals pipeline, February 2019)
- 15 Nov 2018 Chemical structure information added